Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License…
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021 The antibody program selected for development (now known as NKTR-0165) is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021...
Nasdaq GlobeNewswire
24/04/2024
Pharma Parenteral Packaging Market in the North America is Anticipated to…
Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Pharma parenteral packaging is created to hold and transport sterile pharmaceutical goods administered through injections. These packaging techniques keep medical products safe, contamination-free, and undamaged in storage, and transit and maintain their potency. The growing pharmaceutical sector, increasing...
PR Newswire
24/04/2024
Esaote Group: Shareholders' Meeting approves financial statements as of 31…
All the main Group consolidated figures for the 2023 financial year are up: net sales revenues at€ 273.2 million( +6.5%on 2022);EBITDA at€ 41.7 million( +24.5%on 2022) ; Group operating income at€ 13.4 million,( +43%on 2022);consolidated net profit at€ 6.2 million,quadrupled compared to 2022 ( € 1.2 million). " The FY2023 results confirmfurther progress of theGroup , which continues to expand, as evidenced by the 7.6% average annual growth we...
PR Newswire
24/04/2024
TVM Capital Healthcare Announces US$ 17 Million Investment into neurocare
neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in…
PR Newswire
24/04/2024
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05…
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Nasdaq GlobeNewswire
24/04/2024
Bioforum the Data Masters Introduces SUBMIT24: A Free of Charge and…
SUBMIT24 is proud to align with the Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit organization that develops and maintains standards for clinical research. Built on the CDISC standards, SUBMIT24 is designed to streamline the data validation process and enhance efficiency in clinical research. With its user-friendly interface and advanced features, SUBMIT24 empowers users to validate clinical data with ease and accuracy. SUBMIT24 is proud to align with the Clinical...
PR Newswire
24/04/2024
Calliditas Announces Positive NefIgArd Open Label Extension Results
The OLE study was designed to provide 9 months of treatment with Nefecon for all patients who completed the NefIgArd study and who at that time had > 1g/g of proteinuria over 24h and > 30 ml/min of eGFR. All enrolled OLE patients continued on optimized RAS inhibitor therapy (ACEs and/or ARBs) and were treated for 9 months with Nefecon 16mg per day, with a follow-up visit three months after completion of treatment. Primary assessment was based on UPCR and eGFR at 9 months. A total of 119…
PR Newswire
24/04/2024
Tetra Pharm Technologies and Glysious Announce Collaboration to Develop…
Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company's incorporation in 2020. Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to…
PR Newswire
24/04/2024
Precision oncology company Flindr Therapeutics announces €20 million Series A…
The Company utilizes the "ImmunoGram Drug Discovery Engine", which has evolved from seminal work in the laboratories of the Netherlands Cancer Institute (NKI) and the Oncode Institute. This approach involves reverse-translating the heterogeneity in tumor-specific and host-specific factors, as commonly seen in patients in the clinic, into lab-based biological models to screen for and select the most important drug targets involved in patient clinical response. The Company utilizes…
PR Newswire
24/04/2024
135th Canton Fair Showcases Revolutionary Home Furnishing Innovations
ShenZhen ZhongShen AI DI Bedding Technology, stands at the forefront of bedding innovation driven by research and development, producing over 3000 new mattress designs annually including eco-friendly glue-free mattresses, AI smart mattresses, and natural wool mattresses. Their presented technology includes AI intelligent mattress series, leverages AI technology to instantly adapt to users' body characteristics providing an optimized sleep experience through vibration waves combined with sound…
PR Newswire
24/04/2024
SciBase Partners with Al Shirawi Healthcare solutions to Offer Nevisense in UAE
"We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a well-resourced and knowledgeable ally will enable quick market access at a low investment cost. We see this as a way to increase our reach and help more people receive the best care possible," says Pia Renaudin, CEO at SciBase "We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a…
PR Newswire
24/04/2024
Groupe Casino: The New Casino embarks on its transformation plan
The New Casino embarks on its transformation plan An organisation aligned with Casino Group's new scope 1Pooling of support services between brandsRe-internalisation of skillsPlan to strengthen purchasing partnerships with Intermarché and extend such partnerships to AuchanAn employment protection plan that is balanced among the various sites More than 1,000 jobs retained at the Saint-Étienne head officeBetween 1,293 and 3,267 job losses expected A proposed...
Nasdaq GlobeNewswire
24/04/2024
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information...
Nasdaq GlobeNewswire
24/04/2024
Vistin Pharma ASA: First quarter 2024 financial results
thof April 2024Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024.Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023.First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.The net...
Nasdaq GlobeNewswire
24/04/2024
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on…
Press ReleaseNicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of anad hocagentApril 24, 2024 – release at 07:30 CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been...
Nasdaq GlobeNewswire
24/04/2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth…
PARIS, FRANCE, 24 April 2024- Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER 1Growth platforms 2 509.7452.012.8%16.2%New medicines 3 45.514.3n/an/aSomatuline ® 257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5% Total Sales822.4741.910.9%13...
Nasdaq GlobeNewswire
24/04/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in…
Group salesgrew by 2% 1at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies,saleswere 6% lower when reported in CHF Pharmaceuticals Divisionbase business 2 grew by 7%, driven by strong sales of medicines to treat...
Nasdaq GlobeNewswire
24/04/2024
BioSenic postpones its annual general meeting of the shareholders and provides…
PRESS RELEASE - PRIVILEGED INFORMATIONIn view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis....
Nasdaq GlobeNewswire
24/04/2024
Pharming to be honored as Industry Innovator at National Organization for Rare…
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterizedLeiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024. The Rare...
Nasdaq GlobeNewswire
24/04/2024
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides…
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant...
Nasdaq GlobeNewswire
24/04/2024
Novartis and Medicines for Malaria Venture announce positive efficacy and safety…
There is currently no evidence-based treatment for the smallest babies with malariaThe CALINA study tested a new ratio and dose of Coartem ®(artemether- lumefantrine) to account for metabolic differences in babies under 5 kgThe CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024– Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase...
Nasdaq GlobeNewswire
24/04/2024
Glycated Albumin Assay Market Projected to Reach $360.92 million by 2030 -…
The glycated albumin assay, an innovative diagnostic tool, is gaining importance worldwide for its ability to accurately measure glycated albumin levels in the blood, providing an essential alternative for diabetes management, especially for individuals facing inaccuracies with traditional HbA1c tests due to conditions such as hemoglobinopathies, recent blood transfusions, or chronic kidney or liver diseases. This test is essential in modifying diabetes treatment plans swiftly, aiming for…
PR Newswire
24/04/2024
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of…
BOSTON and LONDON, April23, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected...
Nasdaq GlobeNewswire
24/04/2024
Global Corneal Implant Market is Expected to Showcase a Significant Growth at a…
Key Takeaways from the Corneal Implant Market Report Key Takeaways from the Corneal Implant Market Report To read more about the latest highlights related to the corneal implant market, get a snapshot of the key highlights entailed in theGlobal Corneal Implant Market Report Corneal Implant Overview Corneal implants, also known as corneal inlays, are innovative devices designed to correct refractive errors such as presbyopia, a condition where the eye's ability to focus on...
PR Newswire
23/04/2024
Altri Comunicati